1. Dexamethasone inhibits SARS-CoV-2 spike pseudotyped virus viropexis by binding to ACE2
- Author
-
Shiling Hu, Nan Wang, Yongjing Zhang, Zhuoyin Xue, Jue Wang, and Cheng Wang
- Subjects
endocrine system ,Cell ,ACE2 ,Biology ,Article ,Dexamethasone ,Virus ,Cell membrane ,03 medical and health sciences ,Virology ,polycyclic compounds ,medicine ,Humans ,Viability assay ,Binding site ,030304 developmental biology ,0303 health sciences ,Binding Sites ,SARS-CoV-2 ,030302 biochemistry & molecular biology ,HEK 293 cells ,Virus Internalization ,Viropexis ,Molecular biology ,Molecular Docking Simulation ,HEK293 Cells ,medicine.anatomical_structure ,Spike Glycoprotein, Coronavirus ,Angiotensin-converting enzyme 2 ,Angiotensin-Converting Enzyme 2 ,hormones, hormone substitutes, and hormone antagonists ,Protein Binding - Abstract
The SARS-CoV-2 outbreak, began in late 2019, has caused a worldwide pandemic and shows no signs of slowing. Glucocorticoids (GCs), including dexamethasone (DEX), have been widely used as effective anti-inflammatory and immunosuppressant drugs. In this study, seven GCs had no obvious effect on cell viability of angiotensin converting enzyme 2 (ACE2) high expressed HEK293T cells when concentrations were under 10 μM. Molecular docking results revealed that DEX occupied with active binding site of ACE2 of SARS-CoV-2 spike protein. Surface plasmon resonance (SPR) results showed that KD value between DEX and ACE2 was (9.03 ± 0.78) e−6 M. Cell membrane chromatography (CMC) results uncovered that DEX had a chromatographic retention. DEX was found out to inhibiting the viropexis into ACE2h cells using SARS-CoV-2 spike pseudotyped virus. Therefore, DEX inhibits the entrance of SARS-CoV-2 spike pseudotyped virus into cell by binding to ACE2., Highlights •DEX inhibits the entrance of 2019-nCoV spike pseudotyped virus into cells. •DEX can bind to ACE2. •The binding sites of DEX to two proteins interacts with each other when virus entry according to molecular docking.
- Published
- 2021